Feasibility, safety, and preliminary efficacy of a novel ePTFE‐covered self‐expanding stent in saphenous vein graft lesions: The Symbiot II trial
- 25 February 2005
- journal article
- clinical trial
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 64 (3) , 361-368
Abstract
Compared with percutaneous interventions in native coronary arteries, revascularization of saphenous vein graft (SVG) lesions is associated with increased rates of immediate and long‐term major adverse cardiac events (MACE). The Symbiot II trial was a multicenter prospective study designed to evaluate the feasibility and safety of a novel self‐expanding polytetrafluoroethylene (ePTFE)‐covered stent in the treatment of de novo and restenotic SVG lesions. The primary endpoint was MACE through 30 days postprocedure. Successful Symbiot stent deployment was achieved in 75 of 77 patients (97.4%) with SVG lesions ≤ 35 mm in length (visual assessment). The procedural success rate (defined as < 30% residual stenosis at the target site and no clinical complications) was 83%, and all study device procedures provided grade 3 TIMI flow postprocedure. Within the first 30 days postprocedure, four patients (5.2%) experienced MACE (defined as death, Q‐wave or non‐Q‐wave myocardial infarction, and clinically driven target vessel revascularization), of whom three patients (3.9%) experienced periprocedural non‐Q‐wave myocardial infarction. No subacute stent thrombosis was observed over the 6‐month follow‐up period. No relevant luminal loss at the target site (mean, 0.3 ± 0.9 mm) was observed in the 58 patients (77.3% of enrolled patients) who underwent quantitative coronary angiography at 6 months. The incidences of binary in‐stent restenosis, in‐segment restenosis, and target vessel failure (defined as acute and late‐term MACE through 6 months postprocedure) were low (7.0%, 8.6%, and 14.3%, respectively). The Symbiot self‐expanding ePTFE membrane‐covered stent was associated with a high procedural success rate (97.4%), low incidences of MACE at 30 days (5.2%) and 6 months (14.3%), suggesting that it is safe and effective in the treatment of SVG disease. Catheter Cardiovasc Interv 2005;64:361–368.Keywords
This publication has 15 references indexed in Scilit:
- Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass GraftsCirculation, 2002
- Recognition of the Importance of Embolization in Atherosclerotic Vascular DiseaseCirculation, 2000
- Retrieval and analysis of particulate debris after saphenous vein graft interventionJACC, 1999
- Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphologyJACC, 1998
- Stent Placement Compared with Balloon Angioplasty for Obstructed Coronary Bypass GraftsNew England Journal of Medicine, 1997
- Influence of Procedural Success on Immediate and Long-Term Clinical Outcome of Patients Undergoing Percutaneous Revascularization of Occluded Coronary Artery Bypass Vein GraftsJACC, 1996
- Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: The multicenter U.S. Palmaz-Schatz stent experienceJACC, 1995
- Incidence and treatment of 'no-reflow' after percutaneous coronary intervention.Circulation, 1994
- Atherosclerotic saphenous vein grafts treated with different interventional procedures assessed by intravascular ultrasoundAmerican Heart Journal, 1992
- Percutaneous transluminal angioplasty of saphenous vein graft stenosis: long-term follow-upJACC, 1989